The company said, “Reaffirming full year 2025 net product revenue of $820 million to $860 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences reports Q2 adjusted EPS 92c, consensus 96c
- 3 Best Stocks to Buy Now, 7/29/2025, According to Top Analysts
- Harmony Biosciences Holdings: Promising Growth Trajectory with Strong Leadership and Robust Pipeline Supports Buy Rating
- Harmony Biosciences initiated with a Buy at Truist
- Buy Rating Reaffirmed for Harmony Biosciences Amid Promising Orexin-2 Developments and Takeda’s Phase 3 Success